Department of Radiation Oncology, Akdeniz University School of Medicine, Antalya 07070, Turkey.
Department of Radiation Oncology, Izmir City Hospital, İzmir 35510, Turkey.
Curr Oncol. 2024 Nov 2;31(11):6829-6839. doi: 10.3390/curroncol31110504.
The principal objective of this study was to assess the predictive efficacy of the global immune-nutrition-inflammation index (GINI) and the albumin-bilirubin (ALBI) score among patients receiving chemoradiotherapy for esophageal cancer. A retrospective analysis was conducted on 46 patients who received definitive or neoadjuvant radiotherapy for esophageal cancer at our institution. Blood samples were collected from these patients prior to the initiation of radiotherapy to measure the biomarkers, including the C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), the global immune-nutrition-inflammation index (GINI), and the albumin-bilirubin (ALBI) grade. The predictive significance of these biomarkers for progression-free survival (PFS) and overall survival (OS) was evaluated using both univariate and multivariate Cox regression analyses. The median follow-up time for this study was 19.5 months (range: 2.6-166.3 months). Univariate analysis revealed that the platelet count ( = 0.003) and monocyte count ( = 0.04) were significant predictors of PFS. In the multivariate analysis, only the platelet count ( = 0.005) remained an independent predictor of PFS. Univariate analysis demonstrated that the neutrophil count ( = 0.04), lymphocyte count ( = 0.01), NLR ( = 0.005), PLR ( = 0.004), CRP ( = 0.02), ALBI grade ( = 0.01), and GINI ( = 0.005) were significant predictors of OS. Multivariate analysis identified the GINI as a predictor of OS, approaching statistical significance ( = 0.08). The results of our study indicate that the pretreatment GINI and ALBI grades are significantly and independently associated with the OS rates in patients with esophageal cancer who are undergoing chemoradiotherapy.
本研究的主要目的是评估全球免疫-营养-炎症指数（GINI）和白蛋白-胆红素（ALBI）评分在接受食管癌放化疗患者中的预测疗效。对在我院接受根治性或新辅助放疗的 46 例食管癌患者进行回顾性分析。在开始放疗前采集这些患者的血液样本，以测量生物标志物，包括 C 反应蛋白（CRP）、中性粒细胞-淋巴细胞比值（NLR）、血小板-淋巴细胞比值（PLR）、单核细胞-淋巴细胞比值（MLR）、全球免疫-营养-炎症指数（GINI）和白蛋白-胆红素（ALBI）分级。使用单因素和多因素 Cox 回归分析评估这些生物标志物对无进展生存期（PFS）和总生存期（OS）的预测意义。本研究的中位随访时间为 19.5 个月（范围：2.6-166.3 个月）。单因素分析显示血小板计数（ = 0.003）和单核细胞计数（ = 0.04）是 PFS 的显著预测因子。在多因素分析中，只有血小板计数（ = 0.005）仍然是 PFS 的独立预测因子。单因素分析显示中性粒细胞计数（ = 0.04）、淋巴细胞计数（ = 0.01）、NLR（ = 0.005）、PLR（ = 0.004）、CRP（ = 0.02）、ALBI 分级（ = 0.01）和 GINI（ = 0.005）是 OS 的显著预测因子。多因素分析确定 GINI 是 OS 的预测因子，接近统计学意义（ = 0.08）。本研究结果表明，在接受放化疗的食管癌患者中，治疗前 GINI 和 ALBI 分级与 OS 率显著相关，且具有独立性。
